Overview


According to FutureWise analysis, the market for Antifibrinolytic Drugs is expected to grow at a CAGR of 4.10% over the forecast period of 2023-2031. 

Antifibrinolytic drugs constitute a vital class of pharmaceutical agents crucial in managing conditions characterized by excessive bleeding tendencies. These medications give their therapeutic effect by preventing the enzymatic breakdown of blood clots, chiefly mediated by plasmin. The endogenous enzyme plasmin is instrumental in breaking down fibrin, a crucial protein in forming and fortifying blood clots. Antifibrinolytic drugs enhance the resilience and longevity of blood clots, thereby mitigating the risk of profuse bleeding by inhibiting the action of plasmin.

Tranexamic acid is the most widely utilized antifibrinolytic drug known for its high efficacy and relatively favorable safety profile. Tranexamic acid operates by binding to plasminogen, a precursor to plasmin, and preventing its conversion to the active form. This impediment in plasmin generation results in reduced fibrinolysis, reinforcing the stability of existing clots. Another notable antifibrinolytic agent is aminocaproic acid, which shares a similar mechanism of action with tranexamic acid. Epsilon-aminocaproic acid, a derivative of aminocaproic acid, exhibits comparable antifibrinolytic properties and is employed in specific clinical scenarios. The clinical utility of antifibrinolytic drugs spans a diverse array of medical disciplines. These drugs prevent excessive bleeding in surgical settings, particularly high-risk procedures like cardiac surgery or neurosurgery. Moreover, they find application in managing patients with inherited or acquired bleeding disorders, such as hemophilia or von Willebrand disease. In trauma care, antifibrinolytic drugs stem bleeding in cases of severe injury, where rapid and effective clot formation is imperative.

FutureWise Market Research has published a report that provides an insightful analysis of Antifibrinolytic Drugs Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Antifibrinolytic Drugs Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Acic Fine Chems
  • Xanodyne Pharmaceuticals
  • Aurobindo Pharma Ltd
  • Akorn
  • Amerigen Pharms Ltd
  • Mylan
  • Pfizer (GenMed)
  • Sanofi
  • Zydus Cadila
  • Takeda
  • Bayer AG
  • Ferring Holding SA
  • Vitruvias Therapeutics Inc

(Note: The list of the major players will be updated with the latest market scenario and trends)

On the driver side, the rising number of surgical procedures globally is a primary driver. With advancements in medical science and an aging population, there has been a surge in complex surgeries, particularly in critical fields like cardiovascular and neurosurgery. Antifibrinolytic drugs are pivotal in these procedures, ensuring adequate hemostasis and reducing the risk of excessive bleeding.
Moreover, the increasing incidence of hemorrhagic conditions contributes substantially to the market's growth. Factors such as lifestyle changes, greater prevalence of chronic diseases, and improved diagnostics have led to a rise in conditions like hemophilia and von Willebrand disease. This necessitates the use of antifibrinolytic drugs for effective management.
Advancements in healthcare infrastructure, particularly in developing regions, expand the market. Improved access to medical facilities and a greater awareness of the importance of hemorrhage control have bolstered the adoption of antifibrinolytic drugs across various clinical settings.

Several restraints influence the antifibrinolytic market. One primary concern is these drugs' side effects and adverse reactions. While effective in preventing excessive bleeding, antifibrinolytic drugs may lead to adverse events, including thrombosis, allergic reactions, and gastrointestinal disturbances. These potential risks necessitate careful patient selection and monitoring, potentially limiting their use in specific populations. Furthermore, the high cost of antifibrinolytic medications poses a significant challenge. Some of these drugs can be relatively expensive, and this cost may serve as a barrier to access, particularly for patients in regions with limited healthcare resources or inadequate insurance coverage.

By Drug Type

  • Trasylol
  • Aminocaproic Acid
  • Riastap
  • Aprotinin
  • Tranexamic Acid Injection
  • Tranexamic Acid Oral
  • Lysteda
  • Fibrinogen
  • Amicar
  • Cyklokapron

By Application

  • Gynecology
    • Menorrhagia
    • Pregnancy
    • Parturition
    • Gynecological Surgeries
  • Gastrointestinal Bleeding
  • Hereditary Angioedema
  • Hemorrhage
  • Bleeding In Nose And Mouth
  • Fibrinolytic Response Testing
  • Surgeries
    • Dental Surgeries
    • Cardiovascular Surgeries
    • Neurosurgeries

By End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
  • Health Care Specialty Processes

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to the rising number of severe road accidents and trauma. The increasing incidence of platelet dysfunctions, haemophilia A and B, and Von Willebrand disease, which requires antifibrinolytic drugs to inhibit fibrinolysis, is expected to contribute to the market growth in this region. An increased geriatric patient pool, which is more prone to the prevalence of diseases, often requires antifibrinolytics, expanded healthcare infrastructure, a surge in healthcare expenditure, and increased research and development is occurring, which is enhancing the treatment modalities and interventions with more innovations in this region, further driving the market.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on Antifibrinolytic Drugs Market By Drug Type, By Application, By End-User and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections, which are represented in the format of data sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors, which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

 

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.  Antifibrinolytic Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antifibrinolytic Drugs Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.  Antifibrinolytic Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Antifibrinolytic Drugs Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Trasylol
        2. Aminocaproic Acid
        3. Riastap
        4. Aprotinin
        5. Tranexamic acid Injection
        6. Tranexamic Acid Oral
        7. Lysteda
        8. Fibrinogen
        9. Amicar
        10.Cyklokapron

  • 8.  Antifibrinolytic Drugs Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Gynecology
         1.1. Menorrhagia
         1.2. Pregnancy
         1.3. Parturition
         1.4. Gynecological Surgeries
        2. Gastrointestinal Bleeding
        3. Hereditary Angioedema
        4. Hemorrhage
        5. Bleeding In Nose And Mouth
        6. Fibrinolytic Response Testing
        7. Surgeries
         7.1. Dental Surgeries
         7.2. Cardiovascular Surgeries
         7.3. Neurosurgeries

  • 9.  Antifibrinolytic Drugs Market, By End-User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Ambulatory Surgical Centers
        3. Clinics
        4. Health Care Specialty Processes

  • 10.   North America Antifibrinolytic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Antifibrinolytic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Antifibrinolytic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Antifibrinolytic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Antifibrinolytic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Drug Types Offered and Financial Layouts)
    •   1. Acic Fine Chems
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Xanodyne Pharmaceuticals
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Aurobindo Pharma Ltd
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Akorn
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Amerigen Pharms Ltd
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Mylan
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Pfizer (GenMed)
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Sanofi
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Zydus Cadila
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Takeda
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Bayer AG
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Ferring Holding SA
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Vitruvias Therapeutics Inc
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients